Congress trades
BioMarin Pharmaceutical Inc. (BMRN)
About BioMarin Pharmaceutical Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Alexander Hardy
- Employees
- 3,221
- Listed since
- Jul 26, 1999
- Market value
- $12.4B
- Price to earnings
- 169.5
- Earnings per share
- $0.38
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 26, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 6, 2026 | $1.20 | $0.95 | $989.7M | $932.0M | EPS beatRevenue beat |
| Q1 FY2026reported May 4, 2026 | $0.76 | $0.78 | $766.0M | $752.5M | EPS missRevenue beat |
| Q4 FY2025reported Feb 23, 2026 | -$0.24 | $0.17 | $874.6M | $833.7M | EPS missRevenue beat |
| Q3 FY2025reported Oct 27, 2025 | -$0.16 | -$0.15 | $776.1M | $777.5M | EPS missRevenue in line |
| Q2 FY2025reported Aug 4, 2025 | $1.23 | $0.86 | $825.0M | $761.9M | EPS beatRevenue beat |
| Q1 FY2025reported May 1, 2025 | $0.97 | $0.71 | $745.1M | $738.7M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 21, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Alexander HardyPresident and CEO | $1.1M | $16.8M | $4.0M | $21.9M |
| Gregory R. Friberg, M.D.Executive Vice President, Chief Research & Development | $706K | $4.6M | $1.9M | $7.2M |
| Brian R. MuellerExecutive Vice President, CFO | $721K | $4.3M | $1.8M | $6.8M |
| Cristin HubbardExecutive Vice President, Chief Commercial Officer | $662K | $3.5M | $1.6M | $5.7M |
| C. Greg Guyer, Ph.D.Executive Vice President, Chief Technical Officer | $697K | $3.5M | $1.5M | $5.7M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $1.2B | 20,445,212 | +3.2% | 10.60% |
| Dodge & Cox | $849.4M | 14,844,930 | +1.9% | 7.69% |
| Primecap Management Co | $812.0M | 14,190,183 | -0.0% | 7.35% |
| Vanguard Capital Management LLC | $500.3M | 8,743,633 | +1.2% | 4.53% |
| Vanguard Portfolio Management LLC | $494.9M | 8,648,678 | +4.2% | 4.48% |
| Norges Bank | $469.7M | 8,207,954 | +100.0% | 4.25% |
| State Street Corp | $446.4M | 7,800,959 | +6.9% | 4.04% |
| Viking Global Investors LP | $435.8M | 7,616,563 | +7.9% | 3.95% |
| Vestal Point Capital, LP | $344.8M | 6,025,000 | +68.5% | 3.12% |
| AQR Capital Management LLC | $322.5M | 5,699,541 | -25.8% | 2.95% |
| FMR LLC | $276.0M | 4,822,893 | +35.2% | 2.50% |
| Dimensional Fund Advisors LP | $233.2M | 4,075,714 | +7.2% | 2.11% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in BMRN
15 disclosures of 15 on record · median 26d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | -31.7%S&P +88.5% · vs S&P 500 -120.2% | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -28.4%S&P +95.6% · vs S&P 500 -124.0% | Mar 14, 2023 | Apr 7, 2023 | 24d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -18.6%S&P +91.9% · vs S&P 500 -110.6% | May 10, 2022 | Jun 10, 2022 | 31d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -12.9%S&P +70.5% · vs S&P 500 -83.3% | Oct 18, 2021 | Nov 15, 2021 | 28d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $15,001 - $50,000 | -25.9%S&P +105.0% · vs S&P 500 -130.9% | Dec 30, 2020 | Jan 11, 2021 | 12d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -18.7%S&P +119.7% · vs S&P 500 -138.4% | Oct 16, 2020 | Nov 5, 2020 | 20d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -14.7%S&P +124.2% · vs S&P 500 -138.9% | Sep 15, 2020 | Oct 13, 2020 | 28d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -22.9%S&P +138.8% · vs S&P 500 -161.7% | Dec 16, 2019 | Jan 6, 2020 | 21d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -18.2%S&P +142.7% · vs S&P 500 -160.9% | Dec 11, 2019 | Jan 6, 2020 | 26d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -11.8%S&P +165.4% · vs S&P 500 -177.2% | Aug 12, 2019 | Sep 11, 2019 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -20.9%S&P +178.4% · vs S&P 500 -199.3% | Jun 3, 2019 | Jul 11, 2019 | 38d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -24.3%S&P +160.2% · vs S&P 500 -184.4% | Apr 29, 2019 | May 10, 2019 | 11d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -24.5%S&P +161.1% · vs S&P 500 -185.6% | Apr 23, 2019 | May 10, 2019 | 17d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -25.2%S&P +186.3% · vs S&P 500 -211.5% | May 8, 2018 | Jun 8, 2018 | 31d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -23.9%S&P +187.2% · vs S&P 500 -211.2% | May 4, 2018 | May 10, 2018 | 6d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded BMRN?
Daniel S. Goldman, Ro Khanna, Josh Gottheimer, Gilbert Ray Cisneros, Jr. disclosed BMRN transactions in the filings shown here.
How quickly are BMRN trades disclosed?
Congressional disclosures took a median of 26 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.